Targeting ESM1 via SOX4 promotes the progression of infantile hemangioma through the PI3K/AKT signaling pathway
Precision Clinical Medicine · 11.10.2024 · 7 (4)
DOI: 10.1093/pcmedi/pbae026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Precision Clinical Medicine, online erschienen am 09.10.2024. Verfasst von Yanan Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu 610041, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Science & Technology Program of Sichuan Province, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Background
Infantile hemangioma (IH) is the most prevalent benign vascular tumor in children, yet its pathogenesis remains incompletely understood. Research has established a strong association between SOX4 and tumor blood vessel formation. The objective of this study was to investigate the function and underlying mechanism of SOX4 in IH development with the aim of identifying novel therapeutic targets.
Methods
We identified the transcription factor SOX4 associated with IH through RNA-seq screening of IH microtumors and validated it in IH tissues. The effect of SOX4 on the biological behavior of CD31+ hemangioma-derived endothelial cells (HemECs) was investigated via in vitro cell experiments. In addition, RNA-seq analysis was performed on CD31+ HemECs with low expression levels of SOX4, and the target genes of SOX4 were identified. Finally, the effect of SOX4 on tumor angiogenesis was further elucidated through 3D microtumor and animal experiments.
Results
SOX4 is highly expressed in IH tissues and promotes the proliferation, migration, and angiogenesis of CD31+ HemECs. In addition, SOX4 binds to the endothelial cell-specific molecule 1 (ESM1) promoter to promote the progression of the PI3K/AKT signaling pathway. Finally, through IH 3D microtumor and animal experiments, SOX4 and ESM1 are shown to be tumorigenic genes that independently promote tumor progression.
Conclusions
SOX4 plays a crucial role in the progression of IH, and the SOX4/ESM1 axis may serve as a novel biomarker and potential therapeutic target for IH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Oncology, Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
- Department of Pediatric Surgery, Children's Hospital Affiliated to Shandong University, Jinan 25002, China.
Förderung
- National Natural Science Foundation of China
- Science & Technology Program of Sichuan Province
- West China Hospital, Sichuan University
- Natural Science Foundation of Shandong Province
- Sichuan University
- Med-X Center for Informatics
Zitieren
APA
Li, Y., Kong, M., Qiu, T., & Ji, Y. (2024). Targeting ESM1 via SOX4 promotes the progression of infantile hemangioma through the PI3K/AKT signaling pathway. Precision Clinical Medicine, 7(4). https://doi.org/10.1093/pcmedi/pbae026
Vancouver
Li Y, Kong M, Qiu T, Ji Y. Targeting ESM1 via SOX4 promotes the progression of infantile hemangioma through the PI3K/AKT signaling pathway. Precision Clinical Medicine. 2024;7(4). doi:10.1093/pcmedi/pbae026
BibTeX
@article{Li2024,
author = {Li, Yanan and Kong, Meng and Qiu, Tong and Ji, Yi},
title = {Targeting ESM1 via SOX4 promotes the progression of infantile hemangioma through the PI3K/AKT signaling pathway},
journal = {Precision Clinical Medicine},
year = {2024},
volume = {7},
number = {4},
doi = {10.1093/pcmedi/pbae026}
}
EUVIMED